Periodic Reporting for period 1 - PICARD (Disruptive GPCR Lead Discovery Platform Delivering New and Safer Therapeutics)
Reporting period: 2018-08-01 to 2018-11-30
2. Our commercial feasibility has been established by the large market opportunity, the strong network of collaborators, customers, and institutions, a specific IPR strategy and a commercialization plan designed to lower entry-to-market barriers. We have asserted our Freedom to Operate.
3. Our financial evaluation shows that PICARD will be highly profitable, providing a large ROI, which guarantees the financial viability of the investment. We have also evaluated other sources of funding.